Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03463408 · ClinicalTrials.gov registry record · Early Phase 1
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
A Early Phase 1 study of Sarcoma, sponsored by University of Rochester.
- Active
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT03463408: Active Early Phase 1 study of Sarcoma, sponsored by University of Rochester.
NCT03463408 is a Early Phase 1 study of Sarcoma that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 14 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03463408, a Early Phase 1 study of Sarcoma, is active but no longer recruiting, sponsored by University of Rochester.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
Primary Outcome
Evaluate safety through assessment of adverse events throughout the course of treatment
Conditions Studied
Interventions
- DRUG nivolumab
- DRUG ipilimumab
Study Locations (1)
New York
- James P. Wilmot Cancer Center at University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2026-08-01 |
| Phase | Early Phase 1 |
What the registry record for NCT03463408 still lists
NCT03463408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which nivolumab is the first listed.
NCT03463408 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03463408 about?
NCT03463408 is a clinical study titled "Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma". Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
What is the current status of trial NCT03463408?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2018-07-17. Estimated completion is 2026-08-01.
What conditions does trial NCT03463408 study?
This clinical trial studies the following conditions: Sarcoma.
What interventions are being tested in trial NCT03463408?
The interventions under investigation include: nivolumab (DRUG), ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03463408?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03463408 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03463408's enrollment target sits among peer trials
14 111th of 122 higher than 11 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
ACTIVE NOT RECRUITING · Early Phase 1
-
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
ACTIVE NOT RECRUITING · Early Phase 1
-
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
ACTIVE NOT RECRUITING · Early Phase 1
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy
- NCT07218432 · started 2026-10 · NA
A Study of the TheraBionic P1 Device in Breast Cancer